Abstract
Aim
To investigate the effect of intravenous hydralazine infusion on maternal nitric oxide (NO) levels.
Methods
This pilot study comprised 40 (n = 40) gestations complicated with severe preeclampsia to whom maternal plasma NO levels were determined by chemiluminescence before and after hydralazine administration. Blood pressure values were concomitantly assessed.
Results
After 20 min of intravenous hydralazine infusion blood pressure values decrease significantly in term and preterm gestations. This was accompanied by an overall significant decrease in mean plasma NO values (38.7 ± 12.9 to 35.4 ± 13.9 μmol/L, p < 0.05). Despite this, NO values decreased in 67.5% of cases (a 17.6% from baseline) and increased in 32.5% (a 14.8% from baseline) (p < 0.05 for both). Blood pressure decrease (%) was lower (systolic and diastolic) among those displaying a NO decrement than in the increment group. Interestingly, gestational age was higher in the group displaying decreased NO; however, this did not reach statistical significance (37.5 ± 2.7 vs. 35.9 ± 2.8 weeks, p = 0.08).
Conclusion
The results of this study fail to demonstrate a similar NO secretion after hydralazine infusion in women with severe preeclampsia.
References
Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS (2010) Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 17:511–531
Pridjian G, Puschett JB (2002) Preeclampsia. Part 2: experimental and genetic considerations. Obstet Gynecol Surv 57:619–640
Friedman SA, Taylor RN, Roberts JM (1991) Pathophysiology of preeclampsia. Clin Perinatol 4:661–682
Powers RW, Catov JM, Bodnar LM, Gallaher MJ, Lain KY, Roberts JM (2008) Evidence of endothelial dysfunction in preeclampsia and risk of adverse pregnancy outcome. Reprod Sci 15:374–381
Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB (1994) The role of NO in the pathogenesis of preeclampsia. Am J Obstet Gynecol 171:944–948
Conrad K, Kerchner L, Mosher M (1999) Plasma and 24-h NOx and cGMP during normal pregnancy and preeclampsia in women on a reduced NOx diet. Am J Physiol 277:F48–F57
Begum S, Yamasaki M, Mochizuki M (1996) Urinary levels of nitric oxide metabolites in normal pregnancy and preeclampsia. J Obstet Gynaecol Res 22:551–559
Steinert JR, Wyatt AW, Poston L, Jacob R, Mann GE (2002) Preeclampsia is associated with altered Ca2+ regulation and NO production in human fetal venous endothelial cells. FASEB J 16:721–723
Chen LK, Huang CH, Yeh HM et al (2007) Polymorphisms in the endothelial nitric oxide synthase gene may be protective against preeclampsia in a Chinese population. Reprod Sci 14:175–181
Bernardi F, Constantino L, Machado R, Petronilho F, Dal-Pizzol F (2008) Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women. J Obstet Gynaecol Res 34:957–963
Matsubara K, Matsubara Y, Hyodo S, Katayama T, Ito M (2010) Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. J Obstet Gynaecol Res 36:239–247
Teran E, Escudero C, Moya W (2006) Abnormal release of nitric oxide from nitrosoproteins during preeclampsia. Int J Gynecol Obstet 92:260–261
Teran E, Escudero C, Vivero S, Enriquez A, Calle A (2004) Intraplatelet cyclic guanosine-3′,5′-monophosphate levels during pregnancy and preeclampsia. Hypertens Pregnancy 23:303–308
Diejomaoh FM, Omu AE, Al-Busiri et al (2004) Nitric oxide production is not altered in preeclampsia. Arch Gynecol Obstet 269:237–243
Giles TD (2006) Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 8(12 Suppl 4):2–16
Tacchi D (1961) Peripheral vascular response to hydralazine in toxemia of pregnancy. Obstet Gynecol 18:300–304
Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, López JC; or the HYLA treatment study (2006) Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 128:157–162
Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K (2005) Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 46:63–67
Magee LA, von Dadelszen P (2009) The management of severe hypertension. Semin Perinatol 33:138–142
Bauer JA, Fung HL (1991) Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 84:35–39
Unger P, Berkenboom G, Fontaine J (1993) Interaction between hydralazine and nitrovasodilators in vascular smooth muscle. J Cardiovasc Pharmacol 21:478–483
Münzel T, Kurz S, Rajagopalan S et al (1996) Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 98:1465–1470
Thomas GR, DiFabio JM, Gori T, Parker JD (2007) Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 49:1289–1295
Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P (2003) Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 327:955–965
Ellershaw DC, Gurney AM (2001) Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery. Br J Pharmacol 134:621–631
Duley L, Meher S, Abalos E (2006) Management of pre-eclampsia. BMJ 332:463–468
Begum MR, Quadir E, Begum A, Akhter S, Rahman K (2002) Management of hypertensive emergencies of pregnancy by hydralazine bolus injection vs continuous drip: a comparative study. Medscape Women’s Health 7:1
Lopez-Jaramillo P, Narvaez M, Calle A et al (1996) Cyclic guanosine 3′,5′ monophosphate concentrations in pre-eclampsia: effects of hydralazine. Br J Obstet Gynaecol 103:33–38
Echols M, Yancy C (2006) Isosorbide dinitrate hydralazine combination therapy in African American with heart failure. Vasc Health Risk Manag 2:423–431
Terán E, Racines-Orbe M, Vivero S, Escudero C, Molina G, Calle A (2003) Preeclampsia is associated with a decrease in plasma coenzyme Q10 levels. Free Radic Biol Med 35:1453–1456
Mata-Greenwood E, Chen DB (2008) Racial differences in nitric oxide-dependent vasorelaxation. Reprod Sci 15:9–25
Savvidou MD, Vallance PJT, Nicolaides KH, Hingorani AD (2001) Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy. Hypertension 38:1289–1293
Häkli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Endothelial nitric oxide synthase polymorphism in preeclampsia. J Soc Gynecol Investig 10:154–157
Serrano NC, Casas JP, Díaz LA et al (2004) Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case–control study. Hypertension 44:702–707
Sandrim VC, Palei AC, Cavalli RC et al (2008) eNOS haplotypes associated with gestational hypertension or preeclampsia. Pharmacogenomics 9:1467–1473
Heiskanen J, Romppanen EL, Hiltunen M et al (2002) Polymorphism in the tumor necrosis factor-alpha gene in women with preeclampsia. J Assist Reprod Genet 19:220–223
Häkli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia. Genet Test 7:265–268
Xu B, Thornton C, Tooher J et al (2009) Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro. Clin Exp Pharmacol Physiol 36:839–842
Harskamp RE, Zeeman GG (2007) Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci 334:291–295
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Teran, E., Briones, F., Nicolalde, V. et al. Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study. Arch Gynecol Obstet 285, 1183–1187 (2012). https://doi.org/10.1007/s00404-012-2217-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-012-2217-6